" class="no-js "lang="en-US"> Kenneth Kovan - Medtech Alert
Friday, April 19, 2024
Kenneth Kovan

Kenneth Kovan

About Kenneth Kovan

Corporate development professional experienced in transactional business development, strategic partnering, business planning, corporate finance, alliance management, intellectual property, technology licensing, new product development, and brand management. Fortune 500, mid-cap, and early-stage public (CSE, OTCQB) and private company background. Founder of multiple life science companies. Accredited investor.

Related Story

BioVaxys Enters Critical Tumor Cell Supply Agreement with Deaconess Research Institute for BVX-0918 Bioproduction

April 26 2022

BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB,OTCQB:BVAXF) (“BioVaxys” or “Company”), announced today that it has entered […]